Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takenoue, T.
Right arrow Articles by Muto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takenoue, T.
Right arrow Articles by Muto, T.
Related Collections
Right arrow Chemotherapy
Right arrow Prognostic factors
Right arrow Surgery

Annals of Surgical Oncology, Vol 7, Issue 3 193-198, Copyright © 2000 by Society of Surgical Oncology


ARTICLES

Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method

T. Takenoue, H. Nagawa, K. Matsuda, S. Fujii, M. E. Nita, K. Hatano, J. Kitayama, T. Tsuruo and T. Muto
Department of Surgical Oncology, University of Tokyo, Japan. takenoue-1su@h.u-tokyo.ac.jp

BACKGROUND: Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma. Recent researchers indicate that the chemosensitivity of 5-FU for colorectal carcinoma with low expression of TS is better than tumors with high expression of TS. But the relation between TS expression and overall survival of curatively resected colorectal cancer patients has been less studied. METHODS: Specimens of curatively resected colon carcinoma from 148 patients were included in this study. TS expression in the tumor was assessed by immunohistochemical staining technique, and the patients were categorized into TS-(+) and TS-(-) groups. First, the relation between TS expression and survival of patients was examined. Next, for each group, we compared survival between the chemotherapy-(+) and the chemotherapy-(-) subgroup. RESULTS: Overall survival was significantly better in the TS-(-) group (n = 107) than in the TS-(+) group (n = 41) (P = .0003). In the TS-(-) group, there was little difference between the chemotherapy-(+) and the chemotherapy-(-) subgroup. In the TS-(+) group, the survival of the chemotherapy-(+) subgroup was significantly better than the chemotherapy-(-) subgroup (P = .0439). CONCLUSIONS: TS, itself, may be a prognostic factor for colon carcinoma; and 5-FU adjuvant chemotherapy may be appropriate for colon carcinoma with high expression of TS.


This article has been cited by other articles:


Home page
Ann OncolHome page
R. Soong, N. Shah, M. Salto-Tellez, B. C. Tai, R. A. Soo, H. C. Han, S. S. Ng, W. L. Tan, N. Zeps, D. Joseph, et al.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
Ann. Onc., May 1, 2008; 19(5): 915 - 919.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. L. Westra, H. Hollema, M. Schaapveld, I. Platteel, K. A. Oien, W. N. Keith, R. Mauritz, G. J. Peters, C. H. C. M. Buys, R. M. W. Hofstra, et al.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients
Ann. Onc., October 1, 2005; 16(10): 1646 - 1653.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren
Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information
J. Clin. Oncol., August 20, 2005; 23(24): 5628 - 5634.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. D. Ahlgren
Thymidylate Synthase in Nodal Metastases: Prognostic for Chemosensitivity But Not for Adjuvant Therapy?
J. Clin. Oncol., August 20, 2005; 23(24): 5452 - 5454.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Shichijo, K. Azuma, N. Komatsu, M. Ito, Y. Maeda, Y. Ishihara, and K. Itoh
Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer
Clin. Cancer Res., September 1, 2004; 10(17): 5828 - 5836.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Popat, A. Matakidou, and R. S. Houlston
Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis
J. Clin. Oncol., February 1, 2004; 22(3): 529 - 536.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
K.-J. Sohn, R. Croxford, Z. Yates, M. Lucock, and Y.-I. Kim
Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Chemosensitivity of Colon and Breast Cancer Cells to 5-Fluorouracil and Methotrexate
J Natl Cancer Inst, January 21, 2004; 96(2): 134 - 144.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Kornmann, W. Schwabe, S. Sander, M. Kron, J. Strater, S. Polat, E. Kettner, H. F. Weiser, W. Baumann, H. Schramm, et al.
Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression Levels: Predictors for Survival in Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil
Clin. Cancer Res., September 15, 2003; 9(11): 4116 - 4124.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. C. Hu, R. A. Komorowski, S. Graewin, G. Hostetter, O.-P. Kallioniemi, H. A. Pitt, and S. A. Ahrendt
Thymidylate Synthase Expression Predicts the Response to 5-Fluorouracil-based Adjuvant Therapy in Pancreatic Cancer
Clin. Cancer Res., September 15, 2003; 9(11): 4165 - 4171.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Tsuji, S. Hidaka, T. Sawai, T. Nakagoe, H. Yano, M. Haseba, H. Komatsu, H. Shindou, H. Fukuoka, M. Yoshinaga, et al.
Polymorphism in the Thymidylate Synthase Promoter Enhancer Region Is Not an Efficacious Marker for Tumor Sensitivity to 5-Fluorouracil-based Oral Adjuvant Chemotherapy in Colorectal Cancer
Clin. Cancer Res., September 1, 2003; 9(10): 3700 - 3704.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Graziano and S. Cascinu
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
Ann. Onc., July 1, 2003; 14(7): 1026 - 1038.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand
Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
M. Derenzini, L. Montanaro, A. Chilla, E. Tosti, C. Ceccarelli, F. Dall'Olio, D. Ofner, and D. Trere
Evaluation of Thymidylate Synthase Protein Expression by Western Blotting and Immunohistochemistry on Human Colon Carcinoma Xenografts in Nude Mice
J. Histochem. Cytochem., December 1, 2002; 50(12): 1633 - 1640.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pathol.Home page
M Derenzini, L Montanaro, D Trere, A Chilla, P L Tazzari, F Dall'Olio, and D Ofner
Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines
Mol. Pathol., October 1, 2002; 55(5): 310 - 314.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Allegra
Thymidylate Synthase Levels: Prognostic, Predictive, or Both?
J. Clin. Oncol., April 1, 2002; 20(7): 1711 - 1713.
[Full Text] [PDF]


Home page
JCOHome page
D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren
Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy
J. Clin. Oncol., April 1, 2002; 20(7): 1721 - 1728.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al.
Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer
J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society of Surgical Oncology.